Ashland Inc.

ASH

US0441861046

Diversified Chemicals

Market Closed - Nyse Other stock markets 21:00:02 17/05/2024 BST			5-day change	1st Jan Change
100.1 ^USD	+1.46%		+2.06%	+18.68%

05-08	Ashland Inc. Appoints Ashish K. Kulkarni as Director	CI
05-08	Ashland Inc. Expects Impairment Charges for the Third Quarter of Fiscal 2024	CI

Turnspire Capital Partners LLC entered into a definitive agreement nutraceuticals business of Ashland Inc (NYSE: ASH).

May 06, 2024

Turnspire Capital Partners LLC entered into a definitive agreement nutraceuticals business of Ashland Inc (NYSE: ASH) on May 7, 2024. The transaction is expected to close in the third quarter of 2024.

Latest news about Ashland Inc.

Ashland Inc. Appoints Ashish K. Kulkarni as Director	05-08	CI
Ashland Inc. Expects Impairment Charges for the Third Quarter of Fiscal 2024	05-08	CI
Ashland Inc. Authorizes Quarterly Dividend, Payable on June 15, 2024	05-07	CI
BMO Capital Adjusts Price Target on Ashland to $105 From $97, Maintains Market Perform Rating	05-07	MT
Ashland to Sell Nutraceuticals Business to Turnspire Capital	05-07	MT
Turnspire Capital Partners LLC entered into a definitive agreement nutraceuticals business of Ashland Inc (NYSE: ASH).	05-06	CI
JPMorgan Adjusts Price Target on Ashland to $90 From $88, Maintains Underweight Rating	05-02	MT
UBS Adjusts Ashland Price Target to $116 From $114, Maintains Buy Rating	05-01	MT
Ashland Seeks Bolt-On M&A Opportunities	05-01	CI
Transcript : Ashland Inc., Q2 2024 Earnings Call, May 01, 2024	05-01
Tranche Update on Ashland Inc.'s Equity Buyback Plan announced on June 28, 2023.	04-30	CI
Ashland Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	04-30	CI
Ashland Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2024	04-30	CI
Ashland Inc. Announces Resignation of Ashok Kalyana as Senior Vice President, and General Manager, Life Sciences and Intermediates, Effective May 10, 2024	04-30	CI
Ashland Inc Appoints Scott A. Tozier to its Board of Directors	04-15	CI
North American Morning Briefing : Big Banks Kick -2-	04-12	DJ
Wells Fargo Upgrades Ashland to Overweight From Equalweight, Raises Price Target to $112 From $100	04-11	MT
Active Energy to abandon flagship project in Maine	04-09	AN
UBS Adjusts Ashland Price Target to $114 From $105, Maintains Buy Rating	04-08	MT
North American Morning Briefing : Inflation -2-	03-15	DJ
Jefferies Upgrades Ashland to Buy From Hold, Adjusts Price Target to $126 From $100	03-14	MT
EARNINGS AND TRADING: Challenger signs farm-out; Ricardo revenue up	03-06	AN
AIM WINNERS & LOSERS: Challenger Energy up on Chevron farm-out deal	03-06	AN
Active Energy skyrockets after settling dispute with Player Holdings	03-05	AN
UK service sector continues to grow in February	03-05	AN

Chart Ashland Inc.

Duration

Period

More charts

Company Profile

Ashland Inc. is a global specialty additives and materials company. The Company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical. The Company's segments include life sciences, personal care, specialty additives and intermediates. The life sciences segment is comprised of pharmaceuticals, nutrition, nutraceuticals, agricultural chemicals, diagnostic films and fine chemicals. The personal care segment is comprised of bio functionals, microbial protectants (preservatives), skin care, sun care, oral care, hair care and household solutions. The specialty additives segment is comprised of rheology and additives serving the architectural coatings, construction, energy, automotive and various industrial markets. Its Intermediates segment is comprised of the production of 1,4 butanediol (BDO) and related derivatives, including n-methyl pyrrolidone.

Sector

Diversified Chemicals

Calendar

30/05/2024 - Ex-dividend day

More about the company

Income Statement Evolution

More financial data

Ratings for Ashland Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

100.1 USD

Average target price

110 USD

Spread / Average Target

+9.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diversified Chemicals

	1st Jan change	Capi.
ASHLAND INC.	+18.68%	5.02B
SHIN-ETSU CHEMICAL CO., LTD.	-1.30%	75B
BASF SE	+0.19%	47.43B
DUPONT DE NEMOURS, INC.	+3.87%	33.41B
PIDILITE INDUSTRIES LIMITED	+11.03%	18.24B
EASTMAN CHEMICAL COMPANY	+11.76%	11.8B
SYENSQO SA/NV	+1.70%	10.97B
BRENNTAG SE	-16.29%	10.93B
ASAHI KASEI CORPORATION	-0.10%	9.26B
SRF LIMITED	-8.12%	8.11B

Diversified Chemicals

Ashland Inc.

Equities

ASH

US0441861046

Diversified Chemicals

Turnspire Capital Partners LLC entered into a definitive agreement nutraceuticals business of Ashland Inc (NYSE: ASH).

EPS Revisions